EquityZen vs. Hiive: Pre-IPO Secondary Markets in 2026

The pre-IPO secondary market hit a consolidation turning point in early 2026: Morgan Stanley closed its acquisition of EquityZen on January 27, 2026 and immediately cut buyer-side fees from 5% to 2.5%. Hiive, EquityZen's sharpest competitor, raised a Series B at a $650 million pre-money valuation and chose to stay independent. Both platforms gate access to accredited investors and both let you buy shares of late-stage private companies from employees or early backers who want out. They differ sharply on price, minimum investment, how each trade is structured, and how much price information you receive before you commit capital. This comparison covers what you actually pay, where execution risk lives, and which platform fits your investor profile in 2026.

Two Very Different Approaches to the Same Market

VC-backed employees and early-stage investors can hold paper gains for a decade with no practical exit. Pre-IPO secondary marketplaces exist to give those shareholders a buyer. That is the core business both EquityZen and Hiive are in, but they built very different machines to solve it.

EquityZen, founded in New York in 2013, built its model around pooled special purpose vehicle (SPV) funds. Under this structure, a group of accredited investors collectively purchases a block of shares through a fund. The fund holds the shares, and you hold fund interests. That approach lets EquityZen aggregate demand from smaller investors before approaching the company, and it means you do not appear on the company's cap table as an individual holder.

Hiive, founded in Vancouver in 2021, built an open order book instead, the kind of real-time bid and ask display you would recognize from a public exchange. The platform publishes the Hiive50 index: an equal-weighted price index of the 50 most liquid private names on its marketplace, recalculated hourly, available at no cost to any visitor. The design goal is observable market price before you transact, not pooled capital after the fact.

That structural design difference shapes everything else in this comparison.

EquityZen: A Morgan Stanley Subsidiary Since January 2026

Morgan Stanley announced the EquityZen acquisition on October 29, 2025, and closed it on January 27, 2026, per a Business Wire press release filed that day. The deal price was not publicly disclosed. Within weeks of closing, Morgan Stanley announced a direct fee reduction, dropping EquityZen's standard transaction fee to 2.5% from 5% for most transactions on both sides of a trade, per the Morgan Stanley press release.

Under current pricing on EquityZen's platform, confirmed through EquityZen's Help Center, the platform charges buyers a one-time 2.5% sales fee on investments up to $1 million, dropping to 2% for amounts above that. For Direct Share Acquisitions, where you go directly onto a company's cap table rather than through a fund, the same tiered rate applies up to $10 million. EquityZen does not charge carried interest or annual management fees on standard single-company funds. Multi-company diversified funds do charge carry, per the platform's own offering documents.

Minimum investment on standard deals is $10,000. Select deals allow a $5,000 entry, allocated on a first-come, first-served basis when investors complete their term sheets. EquityZen's own disclosures note that $5,000 minimums are not available on every offering. New deals launch every Tuesday and Thursday at 12:00 p.m. Eastern time.

EquityZen operates as a FINRA-registered broker-dealer through EquityZen Securities LLC. The platform has completed more than 51,000 private placements across nearly 500 private companies since 2013 and serves over 800,000 registered users. The platform states that more than 90% of Standard Deals it offers reach a successful close, a figure it attributes to pre-screening for companies with a strong history of approving transfers and obtaining company approval before closing a fund.

Morgan Stanley's ownership brings distribution reach across 20 million wealth management clients and a direct integration with Carta, the cap table software platform. That means the company managing a private company's equity records may also be routing secondary transactions through EquityZen. For buyers, the main near-term benefit is lower fees. The longer-term question is whether an issuer-aligned model shapes which deals surface on the platform.

Hiive: Open Order Book, Profitable, and Staying Independent

Hiive kicked off its Series B on November 13, 2025, listing its own shares on its own platform at a $650 million pre-money valuation, according to Bloomberg. Platform data shows approximately $13.3 million raised as of December 2025. CEO Sim Desai told Bloomberg in June 2025 that the company was profitable and seeking up to $100 million to accelerate growth. The choice to raise on Hiive's own marketplace rather than through a wirehouse is a deliberate signal: independence is central to Hiive's value proposition on both sides of a trade.

Hiive is a FINRA-registered broker-dealer and SIPC member, based in Vancouver and registered as an exempt market dealer in six Canadian provinces. Its Form CRS, updated June 1, 2026, is the authoritative fee disclosure. Sellers pay commissions up to 5.75% for transactions below $500,000, with the rate decreasing on larger deals. Buyers in private fund offerings pay up to 4.85%, with the rate decreasing for amounts above $250,000. For direct share transfers, Hiive does not separately charge for its Execution and Settlement Services, but brokerage commissions still apply to the brokered component of the transaction.

The standard minimum is $25,000. For top-demand companies, minimums can reach $100,000 to $250,000. From April 2024 through April 2026, Hiive's SPV programs financed 70 deals across 24 companies for $342.7 million from 3,493 investors, according to wiki.private.law, which aggregates Hiive's own disclosed figures.

Scale on Hiive's marketplace has grown beyond niche status: more than $2 billion in active orders, more than $250 million in monthly transaction volume, and the Hiive50 index up roughly 49% in 2025. The platform reports that more than 65% of U.S. decacorns (companies valued above $10 billion) have at least one trade on Hiive, and more than 95% of tier-1 venture capital firms work with the platform in some capacity.

Fees and Minimums Side by Side

The table below draws directly from each platform's regulatory filings and Help Center disclosures as of September 2026. Verify current terms in each offering document before you transact, as fee schedules can change.

Feature	EquityZen	Hiive
Buyer fee	2.5% up to $1M; 2% above $1M	Up to 4.85% (decreases above $250K)
Seller fee	None listed for buyers; post-acquisition disclosures show 2.5% applies to both sides on most deals	Up to 5.75% (decreases above $500K)
Ongoing fees	None on single-company funds; carry applies on multi-company funds	None on standard SPV deals; private fund fees vary
Standard minimum	$10,000 (select deals: $5,000)	$25,000 (top names: $100K to $250K)
Accreditation required	Yes, SEC definition	Yes; some deals require qualified purchaser status
Price discovery	Price set at fund launch date	Live order book with hourly bid and ask data
Ownership	Morgan Stanley subsidiary (since January 2026)	Independent (Series B, December 2025)
Regulatory status	FINRA broker-dealer via EquityZen Securities LLC	FINRA broker-dealer, SIPC member

The Structural Trade-off: SPV vs. Direct Share Transfer

EquityZen routes most retail investors through SPV funds under Regulation D, the federal exemption that allows private placements to accredited investors without full SEC registration. You hold interests in a fund, not shares directly on the company's cap table. That pooled structure lets EquityZen aggregate demand from multiple smaller checks into a single block that is worth a company's legal attention. The company's right of first refusal is triggered on the underlying share transfer to the fund, and EquityZen says it works with companies that have demonstrated a willingness to approve transactions.

Hiive offers both paths. In a direct share transfer, your name goes on the company's cap table as a shareholder of record. In a Hiive SPV, an LLC holds the shares and you hold membership interests in that LLC. Hiive's SPV structure typically charges no management fee and no carried interest, which is unusual for an SPV wrapper product. Neither structure eliminates ROFR risk.

The information gap is the part both platforms underemphasize. You almost never get the company's full cap table, liquidation preference stack, or exact transfer restrictions before you invest. You may be buying common stock that sits below multiple layers of preferred shares. In a $1 billion acquisition where preferred holders collect first, your common position might return little or nothing. Both platforms disclose this risk in offering documents. Read those documents before signing a term sheet.

Execution Risk Every Pre-IPO Buyer Must Understand

Right of first refusal (ROFR) is the single largest execution risk in this asset class. When a shareholder agrees to sell shares to you, the company retains the legal right, usually within 30 days, to step in and buy those shares at the same price you agreed to pay. If the company exercises ROFR, you receive your committed capital back, but you do not receive the investment exposure you were seeking. You also receive no compensation for the time your money sat committed and unavailable.

Hiive's own 2024 disclosure data shows ROFR was exercised in approximately one in six direct-transfer deals, and roughly one in four direct-transfer deals did not reach delivery for any reason. Settlement for direct transfers takes 30 to 90 days. EquityZen reports a 90%-plus success rate on Standard Deals, which it attributes to pre-screening for companies with a history of approving secondary transfers and seeking company approval before closing the fund to new investors.

Three additional risks deserve attention. First, no private company is required to give you financial statements. You invest without the disclosure protections that apply to public companies under the Securities Exchange Act of 1934. Second, bid-ask spreads on illiquid secondary shares are wide. If you need to exit before an IPO or acquisition, you may find no buyers, or buyers only at a steep discount. EquityZen's "Express Deals" feature lets existing fund holders list their interest for sale to another investor on the platform, subject to holding periods and minimum size requirements, but no buyer is guaranteed at any price. Third, company-imposed transfer restrictions can block a sale even after both parties agree on terms. Those restrictions are embedded in shareholder agreements you will not fully see before you commit capital.

Which Platform Fits Your Investor Profile

If you are a first-time pre-IPO buyer, EquityZen is the more appropriate starting point. The $5,000 to $10,000 minimum lets you test this asset class without a large capital commitment. The SPV structure pools you with other investors, so you are not navigating a direct cap table entry alone. Morgan Stanley's backing adds operational scale and institutional infrastructure that a younger independent platform cannot match. The 2.5% buyer fee with no ongoing carry on single-company deals is straightforward to model into expected returns.

If you are a repeat buyer who already understands cap table dynamics, liquidation preference waterfalls, and ROFR mechanics, Hiive's order book offers something EquityZen cannot: observable market price before you commit capital. Seeing what other accredited buyers are willing to bid and what sellers are asking gives you a real anchor for whether a deal is fairly priced relative to the company's last funding round. Hiive's fees are higher on a stated basis (up to 4.85% buyer-side versus EquityZen's 2.5%), but price transparency before you transact is worth paying for when you are writing checks above $100,000 and need to know whether you are buying at a reasonable entry point or an inflated one.

I would not use either platform without reading the complete offering documents, confirming you understand the company's liquidation preference structure, and accepting that this is illiquid capital you may not recover for five to ten years, or at all. Pre-IPO investing rewards investors who treat it as a long-duration, binary-outcome position, not a liquid alternative to public equities.

Frequently Asked Questions

Do both EquityZen and Hiive require accredited investor status?

Yes. Both platforms limit participation to accredited investors as defined by the SEC: individuals with net worth above $1 million (excluding primary residence) or annual income above $200,000 ($300,000 jointly with a spouse). Some Hiive deals are further restricted to qualified purchasers, a higher standard requiring $5 million or more in investments. EquityZen verifies accreditation during account setup. Hiive's Form CRS states that investor status is "seriously verified," and the platform conducts checks before you can place bids or transact.

What happens to my investment if the company exercises its right of first refusal?

You receive your committed capital back, but you do not receive the investment exposure you were seeking. The company steps in as buyer at the same price you agreed to pay, so you miss any upside. Hiive's own 2024 data puts the direct-transfer ROFR rate at approximately one in six transactions. EquityZen mitigates this partly by pre-screening for companies with a pattern of approving secondary transfers, but no platform can eliminate ROFR because it is a contractual right in virtually every private company's shareholder agreement.

Can I sell my pre-IPO position before the company goes public?

Possibly, but there is no guarantee of a buyer at any price. EquityZen's "Express Deals" lets an existing fund investor list their interest for sale to another investor on the platform, subject to minimum holding periods and investment size requirements. Hiive's order book lets you list shares for sale, though transfer restrictions and ROFR rights still apply to any direct share transfer. Treat pre-IPO investments as illiquid capital from day one. Plan for a holding period of several years with no guaranteed exit, and do not commit capital you cannot afford to lock up entirely.

How does Morgan Stanley's ownership change the calculus for EquityZen investors?

The most visible change has been lower fees: the 2.5% rate, cut from 5% immediately after the January 2026 close, directly benefits buyers in the near term. The more nuanced consideration is that EquityZen now operates within an issuer-aligned model, keeping the company's interests at the center of each transaction decision. Morgan Stanley has financial relationships with many of the same private companies whose shares trade on EquityZen through its cap table management services and investment banking coverage. That overlap creates incentive structures that may shape which deals the platform sources or prioritizes. Hiive's independence removes that particular conflict, though Hiive also earns fees from issuers for services it provides to them, which creates its own version of the same tension.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.